Retrospective Study
Copyright ©The Author(s) 2015.
World J Hepatol. Apr 8, 2015; 7(4): 703-709
Published online Apr 8, 2015. doi: 10.4254/wjh.v7.i4.703
Table 1 Characteristics of the study population n (%)
CharacteristicPatients
(n = 107)
Age, yr (mean ± SD)147.5 (± 8.8)
Gender
Male68.2 (73)
Female31.8 (34)
INFL3 polymorphism2
CT56.2 (36)
CC28.1 (18)
TT15.7 (10)
Pre treatment HCV-RNA3
< 600000 UI/mL44.7 (46)
≥ 6000000 UI/mL55.3 (57)
Pre treatment elevated ALT488.5 (92)
Fibrosis5
Mild to moderate659.8 (61)
Advanced740.2 (41)
Steatosis47.6 (51)
BMI (kg/m2) > 2754.2 (58)
Diabetes5.6 (6)
Type of peginterferon
alfa 2a75.7 (81)
alfa 2b24.3 (26)
RBV dose
Fix863.6 (68)
Weight-Based936.4 (39)
80/80/80 adherence1094.4 (101)
Table 2 Association between pre-treatment characteristics and sustained virological response - univariate analyses n (%)
SVR (n = 62)No-SVR (n = 45)OR95%CIP
Age, yr (mean ± SD)147.8 (± 9.1)47.1 (± 8.3)10.965-1.0550.696
Male61.3 (38)77.8 (35)0.4250.190-1.0790.093
INFL3 polymorphism CC231.4 (11)24.1 (7)1.440.475-4.3720.585
3HCV-RNA ≥ 600000 UI/mL44.1 (26)70.5 (31)0.330.145-0.7550.009
Pre treatment elevated ALT486.7 (52)90.9 (40)0.650.183-2.3120.553
Advanced fibrosis5626.7 (16)59.5 (25)0.2470.107-0.5730.001
Steatosis46.8 (29)48.9 (22)0.9190.426-1.9810.847
BMI (kg/m2) > 2746.8 (29)64.4 (29)0.4220.149-0.8920.033
Diabetes2 (1)11 (5)0.1310.015-1.1650.08
Peginterferon alfa 2a75.8 (47)75.6 (34)0.9860.403-2.4131
RBV fix-dose764.5 (40)62.2 (28)1.1040.498-2.4470.841
80/80/80 adherence895.2 (59)93.3 (42)0.750.113-2.5520.919
Table 3 Probability of sustained virological response according to fibrosis grade and pre-treatment hepatitis C virus-RNA
HCV-RNA600000 UI/mLAdvanced fibrosis1Probability (%)95%CI
NoNo81.168.8-93.4
YesNo62.246.6-77.8
NoYes51.831.3-72.3
YesYes29.213.1-45.2